← All trials
NCT06462001
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 10, 2020
- Primary completion
- Dec 1, 2026
- Completion date
- Dec 1, 2026
- First posted
- Jun 17, 2024
- Last posted
- Jun 17, 2024
- Enrollment
- 500
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of NottinghamLead sponsor
- Australian and New Zealand Urogenital and Prostate Cancer Trials GroupCollaborator
- University of Western AustraliaOfficial
- University of SydneyCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.